Abstract Background. The current West Africa Ebola virus disease (EVD) outbreak has
resulted in multiple individuals being medically evacuated to other countries for clinical …

Background TKM-130803, a small interfering RNA lipid nanoparticle product, has been
developed for the treatment of Ebola virus disease (EVD), but its efficacy and safety in …

Background In the wake of the recent outbreak of Ebola virus disease (EVD) in several
African countries, the World Health Organization prioritized the evaluation of treatment with …

Abstract From 2014 to May 2015,> 26 000 Ebola virus disease (EVD) cases were reported
from West Africa. We present a patient with EVD who received brincidofovir and …

Background Available data on the characteristics of patients with Ebola virus disease (EVD)
and clinical management of EVD in settings outside West Africa, as well as the …

RESEARCH consistently provide supportive care, but during the second 2 months, after the
unit was reorganized by a new management team, the unit did provide such care …

The clinical evaluation of convalescent plasma (CP) for the treatment of Ebola virus disease
(EVD) in the current outbreak, predominantly affecting Guinea, Sierra Leone, and Liberia …

Ebola virus disease (EVD) developed in a patient who contracted the disease in Sierra
Leone and was airlifted to an isolation facility in Hamburg, Germany, for treatment. During …

Background Convalescent blood therapy has been a promising form of treatment for Ebola
Virus Disease (EVD), but less attention has been focused on it for treatment. Method We …

Background In March 2014, the World Health Organization was notified of an outbreak of
Zaire ebolavirus in a remote area of Guinea. The outbreak then spread to the capital …